Resident Short Review. SATB2 as an Immunohistochemical Marker for Colorectal Adenocarcinoma. A Concise Review of Benefits and Pitfalls
|
|
- Moris Chase
- 6 years ago
- Views:
Transcription
1 Resident Short Review SATB2 as an Immunohistochemical Marker for Colorectal Adenocarcinoma SATB2 is part of the family of matrix attachment region binding transcription factors, and has developmental roles in craniofacial, neural, and osteoblastic differentiation. Recently, SATB2 has been shown to be highly expressed in the epithelium of the lower gastrointestinal tract, with a relatively narrow expression profile in malignancies, including colorectal/appendiceal adenocarcinomas, tumors of osteoblastic differentiation, and renal/urothelial carcinomas. SATB2 has gained interest as a relatively specific marker of colorectal differentiation, with potential applications including determining origin of adenocarcinomas of unknown primary and distinguishing primary ovarian mucinous adenocarcinomas from colorectal metastases. Here, we briefly review the biology, expression profile, and potential histologic applications of SATB2. (Arch Pathol Lab Med. 2017;141: ; doi: /arpa RS) Colorectal cancer is the fourth most common cancer and the second leading cause of cancer death in the United States. 1 Pathologic identification of colonic adenocarcinoma presenting as a mass in the colon does not generally pose diagnostic difficulties; however, approximately 3% to 5% of all new diagnoses of malignancy present as metastases from a carcinoma of unknown primary. 2 The transcription factor SATB2 was recently identified as a potential marker of high specificity in colorectal adenocarcinoma when used in conjunction with marker CK20. 3 The biology, expression pattern, and potential diagnostic utility and pitfalls of SATB2 will be reviewed in this paper. BIOLOGY OF SATB2 SATB2 was first identified in a complementary DNA sequencing project in 2002, and was then characterized as a A Concise Review of Benefits and Pitfalls Kyra B. Berg, MD; David F. Schaeffer, MD, FRCPC gene involved in isolated cleft palate defects by FitzPatrick et al 4 in Recently, a genetic syndrome associated with SATB2 defects has been described, with a phenotype including intellectual disability, craniofacial abnormalities including cleft palate and dental malformations, and osteopenia. 5 Characterization of the transcription factor mechanism of SATB2 showed it to be part of the matrix attachment region binding transcription factor family, which consists of transcription factors binding to AT-rich regions in the nuclear matrix (matrix attachment regions). 6 These transcription factors are capable of altering chromatin structure over large distances and affecting multiple genes. 6 SATB2 has high levels of expression in the brain, including in the cerebral cortex and the spinal cord, and has a role in central nervous system development. 7 It is highly expressed during the period of cortical neuron differentiation, as well as in specific spinal cord neuron populations. 7,8 SATB2 has also been shown to have a role in osteoblast differentiation via interactions with transcriptional regulator Runx2 and a microrna network. 9,10 Dobreva et al 9 showed that mice with SATB2 defects had global defects in bone formation, as well as craniofacial abnormalities thought to result from the effects on bone formation. More recently, expression of SATB2 has been investigated as a prognostic factor in both colorectal and laryngeal carcinoma. A retrospective analysis of 146 and a prospective cohort of 557 colorectal carcinoma patients both showed that decreased SATB2 expression by immunohistochemistry was associated with a worse prognosis, as well as decreased sensitivity to chemotherapy and radiation, for colonic but not rectal carcinoma. 11,12 Mansour et al 13 showed a tumorsuppressive function for SATB2 in vitro and a potential mechanism of this suppression via inactivation of tumorpromoting factor ERK5. Decreased immunohistochemical expression of SATB2 has also been shown to be a poor prognostic factor for laryngeal squamous cell carcinomas. 14 Accepted for publication October 27, From the Department of Pathology, University of British Columbia, Vancouver, Canada (Dr Berg); and the Department of Pathology, Vancouver General Hospital, Vancouver, British Columbia, Canada EXPRESSION PATTERN OF SATB2 (Dr Schaeffer). The expression pattern of SATB2 was first described in The authors have no relevant financial interest in the products or mouse tissues, and was found to be present in the companies described in this article. Reprints: Kyra B. Berg, MD, Department of Pathology, University of developmental first branchial arch, developing cortical and British Columbia, Room G227, 2211 Wesbrook Mall, Vancouver, BC spinal cord neurons, and developing bones, as well as in V6T2B5, Canada ( kyraberg@alumni.ubc.ca). mature pre-b cells, kidney, brain, testis, and thymus. 4,6,7, Arch Pathol Lab Med Vol 141, October 2017 SATB2 as a Marker for Colorectal Adenocarcinoma Berg & Schaeffer
2 SATB2 was then identified as a potential immunohistochemical marker of human colorectal epithelium through screening of the Human Protein Atlas database by Magnusson et al. 3 The authors characterized the expression profile of SATB2 in normal human tissues using tissue microarrays, and found it to be highly expressed in the epithelium of the lower gastrointestinal tract (including appendix, colon, and rectum), as well as specific neurons (in the cerebral cortex and hippocampus), non germinal center lymphoid cells, and the ductal epithelium of the testis and epididymis. 3 The malignancy expression profile of SATB2 was initially characterized using a tissue microarray of 216 malignancy samples designed to represent the 20 most common human malignancies. 3 Colorectal adenocarcinoma showed strong expression of SATB2 in the majority of samples, and strong expression was also seen in 1 renal cell carcinoma. 3 Weak to moderate SATB2 expression was also seen in sinonasal carcinomas (56%; 5 of 9) and a small percentage of ovarian, breast, lung, and urothelial carcinomas (,7%). 3 Since this initial screen for expression in malignancies, the finding of SATB2 expression in renal carcinoma has been replicated 15,16 ; in the study by Guo et al, 15 26% (19 of 73) of clear cell renal cell carcinomas showed moderate to strong SATB2 staining. In addition to colorectal adenocarcinoma, SATB2 has also been found to be expressed in colorectal medullary carcinoma (16 of 18 cases). 17 SATB2 has also recently been reported to be expressed in Merkel cell carcinomas, with 75% (15 of 20) of cases in one study expressing SATB2, the same number as were expressing CK20 in the characteristic perinuclear pattern. 16,18 SATB2 has also been shown to be highly expressed in tumors of osteoblastic differentiation, including osteosarcomas and several benign bone tumors, and in some softtissue malignancies, including liposarcomas. 19,20 Incisional biopsies of osteoblastic tumors (which had no or brief decalcification) stained more diffusely and at a higher rate (56% versus 45%) than resection specimens that had been subjected to decalcification, indicating that SATB2 immunohistochemistry is sensitive to decalcification and ideally would be performed on the biopsy. 20 POTENTIAL DIAGNOSTIC UTILITY OF SATB2 Identification of the primary location of adenocarcinoma presenting as a metastasis is a common diagnostic problem in anatomical pathology, and immunohistochemistry can be a helpful tool in addition to morphologic features, especially in poorly differentiated adenocarcinomas. A common approach to the immunohistochemical identification of metastatic colorectal adenocarcinoma is the use of the typical immunostaining pattern 21,22 CK7, CK20 þ, and CDX2 þ (see Figure 1, A through D). However, CDX2 and CK20 have been shown to be positive in up to 21%/21% of gastric and 14%/21% of ovarian mucinous adenocarcinomas, respectively, and CK7 was not particularly helpful in this differential, as it was positive in only about 50% of gastric and ovarian mucinous adenocarcinomas. 21 This combination was more helpful in differentiating colorectal from pancreatic adenocarcinoma, which was only 2% CDX2 þ, 15% CK20 þ, and predominantly CK7 þ (94%), and with only 3% of colorectal adenocarcinoma being CK7 þ. 21 Bayrak et al 22 compared the use of the CK7 CK20 þ pattern, which had a sensitivity of 64% and specificity of 97%, with use of CDX2 positivity, which had a 78% sensitivity and 85% specificity in differentiating colorectal from gastric and pancreatic adenocarcinoma. These and other studies have demonstrated the need for a better marker in differentiating colorectal from gastric, pancreatic, and ovarian mucinous adenocarcinoma. The initial identification of SATB2 as a potential marker of colorectal adenocarcinoma by Magnusson et al 3 was followed by validation using colorectal cancer tissue from 9 different research cohorts (1558 localized and 252 metastatic colorectal adenocarcinoma). Using SATB2 as a solitary marker, SATB2 was positive in 92.4% (110 of 119) of stage I, 91.4% (402 of 440) of stage II, and 83.7% (431 of 515) of stage III/IV colorectal adenocarcinomas. Based on these results, and the results of the tissue microarray from other common malignancies, Magnusson et al 3 suggested that the combination of SATB2 with CK20 is a highly specific marker for colorectal adenocarcinoma. In a prospective study of 840 cases in which CK20 was being used to reach a final diagnosis, Dragomir et al 16 analyzed the expression of SATB2. As a solitary marker, SATB2 had a 93% sensitivity and 77% specificity in diagnosing colorectal adenocarcinoma, but when used as a combined marker along with CK20 positivity and CK7 negativity the sensitivity was 83% and the specificity was 100%. 16 As a comparison, the sensitivity and specificity of the CK7 CK20 þ immunophenotype were 85% and 99%, respectively, and for the CDX2 þ immunophenotype these were 96% and 80%. Thus, the addition of SATB2 to the standard CK7 and CK20 panel did not significantly improve the sensitivity or specificity for diagnosis of colorectal carcinoma. Another potential application of SATB2 is to distinguish adenocarcinomas of colorectal origin from those of gastric and pancreatic origin, which are common differentials. Lin et al 17 looked at SATB2 expression in 1941 malignancy cases using tissue microarrays. They found SATB2 to be highly expressed in colorectal adenocarcinoma (96.8%; 121 of 125), with low expression in gastric adenocarcinoma (0%; 0 of 20) and pancreatic adenocarcinoma (4.2%; 4 of 95). This finding of low SATB2 expression in gastric and pancreatic adenocarcinomas has been replicated in other studies (see Table), and is promising for this particular application of SATB2. 3,17,23 However, in contrast to the results from other studies, Dragomir et al 16 had a 22% SATB2 positivity in both gastroesophageal and pancreatobiliary cancer. Possible reasons for discrepancies include use of a different SATB2 antibody clone (see Table) and a low threshold for positivity (2%), used elsewhere only by Magnusson et al 3 (the other referenced studies used 5% to 25%, or a moderate cutoff). With regard to gastric cancer, Dragomir et al 16 included only 9 cases, and did not distinguish between gastric and esophageal cancers or the pathologic subtype. Interestingly, Lin et al 17 showed 6.7% SATB2 positivity in esophageal adenocarcinoma, so esophageal carcinoma may partially account for the high rate in the Dragomir et al 16 study. The malignancy panel by Lin et al 17 also showed low rates of SATB2 expression in lung and gynecologic malignancies, including 3% (6 of 198) of lung adenocarcinomas, 11% (13 of 121) of lung squamous cell carcinomas, 5% (5 of 55) of endocervical adenocarcinomas, and 4% (5 of 131) of endometrial adenocarcinomas. This finding of SATB2 expression in a low percentage of lung and gynecologic adenocarcinomas, which may be differential diagnoses in adenocarcinomas of unknown primary, was also seen in the Dragomir et al 16 study. Arch Pathol Lab Med Vol 141, October 2017 SATB2 as a Marker for Colorectal Adenocarcinoma Berg & Schaeffer 1429
3 Figure 1. Typical immunohistochemical staining pattern of colorectal adenocarcinoma (hematoxylin-eosin, original magnification 340 [A]; immunohistochemical stain for CK7, original magnification 340 [B]; immunohistochemical stain for CK20, original magnification 340 [C]; immunohistochemical stain for SATB2, original magnification 340 [D]). A commonly encountered diagnostic problem in day-today anatomic pathology is intestinal-type mucinous carcinomas of the ovary, with the differential diagnosis being a primary ovarian mucinous adenocarcinoma or a metastatic colorectal/appendiceal adenocarcinoma. CK7, CK20, and CDX2 have all been used to help distinguish these entities, with ovarian mucinous carcinoma being primarily CK7 þ CK20 CDX2 and colorectal/appendiceal carcinoma being primarily CK7 CK20 þ CDX2 þ, but there is a significant degree of overlap. 24 Prior to the discovery of SATB2, CDX2 was the most specific marker available, present in 60% to 100% of colorectal carcinomas but strongly positive in only up to 18% of ovarian mucinous carcinomas. 24 Two recent studies have shown SATB2 to be a specific marker of colorectal or appendiceal metastases versus primary ovarian mucinous carcinomas. 23,24 Montiel et al 24 studied immunohistochemical profiles of 51 primary ovarian mucinous tumors (including cystadenomas, borderline tumors, and adenocarcinomas) and 20 colorectal/ appendiceal ovarian metastases. They found SATB2 to be expressed in 95% of the metastases and 0% of the ovarian primaries (versus 95% and 13% for CDX2). 24 Moh et al 23 examined SATB2 expression in 111 primary ovarian tumors and 46 colorectal/appendiceal ovarian metastases, and found SATB2 expression in 1 borderline tumor and no adenocarcinomas versus 78% of the metastases. In both studies, SATB2 was highly specific for colorectal and appendiceal metastases versus primary ovarian mucinous tumors,withtheexceptionthatsatb2wasfoundtobe expressed in associated teratomas of ovarian primaries (see Table). 23,24 The utility of SATB2 as a marker for metastatic colorectal adenocarcinoma in 111 cytology specimens was assessed as compared with a standard panel of CK7, CK20, and CDX2. 25 Use of SATB2 as a solitary marker had a sensitivity of 60% and a specificity of 91%, whereas the standard panel had a sensitivity of 79% and a specificity of 100%. When SATB2 was added to the standard panel, there was no significant difference in predictive value. The conclusion was that SATB2 did not add any additional value to the standard panel for diagnosing colorectal metastases in cytology specimens. 25 INSTITUTION-SPECIFIC EXPERIENCE WITH SATB2 SATB2 had been in use as an immunohistochemical marker at Vancouver General Hospital in Vancouver, Canada, for 6 months when this article was written. The majority of cases expressing SATB2 (23 of 34) have been colorectal or appendiceal adenocarcinomas. Conversely, the majority of colorectal and appendiceal adenocarcino Arch Pathol Lab Med Vol 141, October 2017 SATB2 as a Marker for Colorectal Adenocarcinoma Berg & Schaeffer
4 Summary of Immunohistochemical Staining Results From 6 Studies for SATB2, CDX2, CK20, and CK7 in Colorectal/ Appendiceal, Gastric, Pancreatic, and Ovarian Mucinous Adenocarcinomas Study Pathologic Diagnosis SATB2, CDX2, CK20, CK7, SATB2 Ab Clone Magnusson et al, Colorectal adenocarcinoma 86 (1558) 96 (245) 93 (245)... Polyclonal a Bayrak et al, Colorectal adenocarcinoma (118) 84 (118) 22 (118)... Dragomir et al, Colorectal adenocarcinoma 94 (51) 96 (51) CL0276 Lin et al, Colorectal adenocarcinoma 97 (125) SATBA4B10 b Moh et al, Colorectal adenocarcinoma 71 (251) EPNCIR130A Montiel et al, Colorectal/appendiceal 95 (20) 95 (20) 100 (20) 10 (20) SATBA4B10 adenocarcinoma (ovarian metastasis) Moh et al, Colorectal/appendiceal 78 (46) 100 (31) c 100 (31) c 19 (31) EPNCIR130A adenocarcinoma (ovarian metastasis) Brandler et al, Colorectal adenocarcinoma 60 (43) 98 (43) 93 (43) 14 (43) Not specified (metastasis, FNA) Magnusson et al, Gastric cancer, unspecified 0 (25) (25)... Polyclonal a Bayrak et al, Gastric adenocarcinoma (59) 53 (59) 80 (59)... Dragomir et al, Gastroesophageal 22 (9) (9)... CL0276 carcinoma Lin et al, Gastric adenocarcinoma 0 (20) SATBA4B10 b Moh et al, Gastric adenocarcinoma 0 (5) EPNCIR130A Moh et al, Gastric adenocarcinoma 0 (9) 100 (5) c 100 (5) c 80 (5) EPNCIR130A (ovarian metastasis) Magnusson et al, Pancreatic cancer, 0 (25) (25)... Polyclonal a unspecified Bayrak et al, Pancreatic adenocarcinoma (32) 22 (32) 97 (32)... Dragomir et al, Pancreatobiliary carcinoma 22 (41) (41)... CL0276 Lin et al, Pancreatic adenocarcinoma 4.2 (95) SATBA4B10 b Moh et al, Pancreatic adenocarcinoma 0 (18) EPNCIR130A Moh et al, Pancreatic adenocarcinoma 0 (6) EPNCIR130A (ovarian metastasis) Brandler et al, Pancreatic adenocarcinoma 6 (18) 33 (18) 22 (18) 89 (18) Not specified (metastasis, FNA) Magnusson et al, Ovarian cancer, 3 (154) Polyclonal a unspecified Montiel et al, Ovarian mucinous tumors d 0 (55) 13.1 (55) 73 (55) 98 (55) SATBA4B10 Moh et al, Ovarian mucinous 0 (17) 80 (10) c 80 (10) c 100 (10) EPNCIR130A adenocarcinoma Brandler et al, Ovarian adenocarcinoma (metastasis, FNA) 0 (4) 0 (4) 0 (4) 100 (4) Not specified Abbreviation: FNA, fine-needle aspiration. a Validated against SATBA4B10, Abcam polyclonal AB34735, Atlas CAB b As well as EPNCIR130b. c for CDX2 and/or CK20. d Mucinous cystadenomas, mucinous borderline, and mucinous adenocarcinomas. mas have stained positively with SATB2, with only 2 cases of 25 colorectal adenocarcinomas staining negatively for SATB2. Both negative cases were poorly differentiated, which is in line with the original results from Magnusson et al, 3 with intact DNA mismatch repair proteins, and one had undergone osseous metaplasia. Thus, in our institution, SATB2 has a sensitivity of 92% and specificity of 75% for diagnosis of colorectal and appendiceal adenocarcinoma, which is comparable with the results for surgical specimens in the study by Dragomir et al 16 (93% and 77%, respectively). Also in line with previous results, there have been 1 case of papillary renal cell carcinoma (see Figure 2, A through C), 1 urothelial carcinoma with intestinal differentiation, and 1 urothelial villous adenoma that have stained positively with SATB2. Unexpected findings of malignancies staining with SATB2 include a desmoplastic mesothelioma (see Figure 2), a rectal neuroendocrine carcinoma, a poorly differentiated pancreatic adenocarcinoma, and a mucinous adenocarcinoma of the prostate. In addition, there was 1 case of a primary ovarian mucinous adenocarcinoma with intestinal differentiation, arising in a borderline mucinous tumor, which is the first reported ovarian mucinous adenocarcinoma staining with SATB2 (see Figure 2). CLINICAL IMPLICATIONS SATB2 has been shown to be highly expressed in the lower gastrointestinal tract and adenocarcinomas of colorectal and appendiceal origin, as well as in osteoblasts and tumors of osteoblastic differentiation, and moderately expressed in renal tissues and some renal/urothelial tumors. Many studies have now shown a high specificity for SATB2 in distinguishing adenocarcinomas of colorectal and appendiceal origin, but have not shown sensitivity and specificity improving on the standard panel of CK7, CK20, and CDX2. In addition, the expression of SATB2 seems to decrease in poorly differentiated adenocarcinoma, which is the most common situation in which this marker would be needed, and this diagnostic observation also appears to correspond Arch Pathol Lab Med Vol 141, October 2017 SATB2 as a Marker for Colorectal Adenocarcinoma Berg & Schaeffer 1431
5 Figure 2. A, SATB2-positive ovarian mucinous adenocarcinoma. B, SATB2-positive desmoplastic mesothelioma. C, SATB2-positive papillary renal cell carcinoma (hematoxylin-eosin, original magnifications 340 [A] and 3100 [B and C]; immunohistochemical stain for SATB2, original magnifications 340 [A inset] and 3100 [B and C insets]). with prognostic data indicating a poorer prognosis with decreased SATB2 expression. One potential specific useful application of SATB2 is in differentiating colorectal/appendiceal adenocarcinomas from ovarian mucinous adenocarcinomas, with 2 papers showing a high specificity for SATB2 in this application. However, in the short time SATB2 has been in use in our institution, we have already seen 1 case of SATB2-positive ovarian mucinous adenocarcinoma. Another potential specific application of SATB2 is in distinguishing adenocarcinoma of colorectal/appendiceal from that of gastric and pancreatic origin, with promising results from studies thus far, and it would be interesting to see a study specifically addressing this question. Despite these relative shortcomings, SATB2 is a robust marker if used within a panel approach. The data thus far seem to indicate that SATB2 is a less sensitive but more specific marker of colorectal and appendiceal origin than CDX2 for an adenocarcinoma of unknown origin. References 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, CA Cancer J Clin. 2016;66(1):7 30. doi: /caac Conner JR, Hornick JL. Metastatic carcinoma of unknown primary: diagnostic approach using immunohistochemistry. Adv Anat Pathol. 2015; 22(3): doi: /pap Magnusson K, de Wit M, Brennan DJ, et al. SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol. 2011;35(7): doi: /pas.0b013e31821c3dae. 4. FitzPatrick DR, Carr IM, McLaren L, et al. Identification of SATB2 as the cleft palate gene on 2q32 q33. Hum Mol Genet. 2003;12(19): doi: /hmg/ddg Zarate YA, Perry H, Ben-Omran T, et al. Further supporting evidence for the SATB2-associated syndrome found through whole exome sequencing. Am J Med Genet A. 2015;167A(5): doi: /ajmg.a Dobreva G, Dambacher J, Grosschedl R. SUMO modification of a novel MAR-binding protein, SATB2, modulates immunoglobulin mu gene expression. Genes Dev. 2003;17(24): doi: /gad Britanova O, Akopov S, Lukyanov S, Gruss P, Tarabykin V. Novel transcription factor Satb2 interacts with matrix attachment region DNA elements in a tissue-specific manner and demonstrates cell-type-dependent expression in the developing mouse CNS. Eur J Neurosci. 2005;21(3): doi: /j x. 8. Gyorgy AB, Szemes M, de Juan Romero C, Tarabykin V, Agoston DV. SATB2 interacts with chromatin-remodeling molecules in differentiating cortical neurons. Eur J Neurosci. 2008;27(4): doi: /j x. 9. Dobreva G, Chahrour M, Dautzenberg M, et al. SATB2 is a multifunctional determinant of craniofacial patterning and osteoblast differentiation. Cell. 2006; 125(5): doi: /j.cell Hassan MQ, Gordon JAR, Beloti MM, et al. A network connecting Runx2, SATB2, and the mir-23a~27a~24-2 cluster regulates the osteoblast differentiation program. Proc Natl Acad Sci U S A. 2010;107(46): doi: /pnas Wang S, Zhou J, Wang X, et al. Down-regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancer. J Pathol. 2009;219(1): doi: /path Eberhard J, Gaber A, Wangefjord S, et al. A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer. Br J Cancer. 2012;106(5): doi: /bjc Mansour MA, Hyodo T, Ito S, et al. SATB2 suppresses the progression of colorectal cancer cells via inactivation of MEK5/ERK5 signaling. FEBS J. 2015; 282(8): doi: /febs Liu T-R, Xu L-H, Yang A-K, et al. Decreased expression of SATB2: a novel independent prognostic marker of worse outcome in laryngeal carcinoma patients. PLoS One. 2012;7(7):e doi: /journal.pone Guo C, Xiong D, Yao X, et al. Decreased SATB2 expression is associated with metastasis and poor prognosis in human clear cell renal cell carcinoma. Int J Clin Exp Pathol. 2015;8(4): Dragomir A, de Wit M, Johansson C, Uhlen M, Ponten F. The role of SATB2 as a diagnostic marker for tumors of colorectal origin: results of a pathologybased clinical prospective study. Am J Clin Pathol. 2014;141(5): doi: /AJCPWW2URZ9JKQJU. 17. Lin F, Shi J, Zhu S, et al. Cadherin-17 and SATB2 are sensitive and specific immunomarkers for medullary carcinoma of the large intestine. Arch Pathol Lab Med. 2014;138(8): doi: /arpa oa. 18. Fukuhara M, Agnarsdóttir M, Edqvist P-H, Coter A, Ponten F. SATB2 is expressed in Merkel cell carcinoma. Arch Dermatol Res. 2016;308(6): doi: /s Ordóñez NG. SATB2 is a novel marker of osteoblastic differentiation and colorectal adenocarcinoma. Adv Anat Pathol. 2014;21(1): doi: / PAP Conner JR, Hornick JL. SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours. Histopathology. 2013;63(1): doi: /his Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res. 2005;11(10): doi: / ccr Arch Pathol Lab Med Vol 141, October 2017 SATB2 as a Marker for Colorectal Adenocarcinoma Berg & Schaeffer
6 22. Bayrak R, Haltas H, Yenidunya S. The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7 /20þ phenotype is more specific than CDX2 antibody. Diagn Pathol. 2012;7(1):1 11. doi: / Moh M, Krings G, Ates D, Aysal A, Kim GE, Rabban JT. SATB2 expression distinguishes ovarian metastases of colorectal and appendiceal origin from primary ovarian tumors of mucinous or endometrioid type. Am J Surg Pathol. 2016;40(3): doi: Montiel DP, Angulo KA, León DC, Quevedo LB, Vilchis JC, Montalvo LH. The value of SATB2 in the differential diagnosis of intestinal-type mucinous tumors of the ovary: primary vs metastatic. Ann Diagn Pathol. 2015;19(4): doi: /j.anndiagpath Brandler TC, Jelloul F, Soto D, Das K, Rosen L, Bhuiya TA. Young investigator challenge: cadherin-17 and SATB2 in cytology specimens: do these new immunostains help in differentiating metastatic colorectal adenocarcinoma from adenocarcinomas of other origins? Cancer Cytopathol. 2015;123(12): doi: /cncy Arch Pathol Lab Med Vol 141, October 2017 SATB2 as a Marker for Colorectal Adenocarcinoma Berg & Schaeffer 1433
Presentation material is for education purposes only. All rights reserved URMC Radiology Page 1 of 98
Presentation material is for education purposes only. All rights reserved. 2011 URMC Radiology Page 1 of 98 Radiology / Pathology Conference February 2011 Brooke Koltz, Cytopathology Resident Presentation
More informationCancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC
Cancers of unknown primary : Knowing the unknown Prof. Ahmed Hossain Professor of Medicine SSMC Definition Cancers of unknown primary site (CUPs) Represent a heterogeneous group of metastatic tumours,
More informationACCURACY OF IMMUNOHISTOCHEMISTRY IN EVALUATION
POL J PATHOL 2011; 2: 95-100 ACCURACY OF IMMUNOHISTOCHEMISTRY IN EVALUATION OF MALIGNANT PLEURAL AND PERITONEAL EFFUSIONS FERESHTEH ENSANI, FARNAZ NEMATIZADEH, GITI IRVANLOU Department of Cytology, Cancer
More informationCarcinoma of unknown primary origin (CUP) is defined
REVIEW ARTICLE Metastatic Carcinoma of Unknown Primary: Diagnostic Approach Using Immunohistochemistry James R. Conner, MD, PhD and Jason L. Hornick, MD, PhD Abstract: Carcinoma of unknown primary origin
More informationHow to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens
How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens Wenxin Zheng, M.D. Professor of Pathology and Gynecology University of Arizona zhengw@email.arizona.edu http://www.zheng.gynpath.medicine.arizona.edu/index.html
More informationNew Developments in Immunohistochemistry for Gynecologic Pathology
New Developments in Immunohistochemistry for Gynecologic Pathology Michael T. Deavers, M.D. Professor, Departments of Pathology and Gynecologic Oncology Immunohistochemistry in Gynecologic Pathology Majority
More informationCase history: Figure 1. H&E, 5x. Figure 2. H&E, 20x.
1 Case history: A 49 year-old female presented with a 5 year history of chronic anal fissure. The patient s past medical history is otherwise unremarkable. On digital rectal examination there was a very
More informationCarcinoma of Unknown Primary (CUP)
Metasta c Carcinoma of Unknown Primary: Diagnos c Approach Using Immunohistochemistry James R. Conner, MD, PhD Mount Sinai Hospital Toronto, ON Carcinoma of Unknown Primary (CUP) 3-5% of all new malignant
More informationTissue-Specific Cadherin CDH17 Is a Useful Marker of Gastrointestinal Adenocarcinomas With Higher Sensitivity Than CDX2
Anatomic Pathology / CDH17 in Gastrointestinal Carcinomas Tissue-Specific Cadherin CDH17 Is a Useful Marker of Gastrointestinal Adenocarcinomas With Higher Sensitivity Than CDX2 Nicole C. Panarelli, MD,
More informationMEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site
POLICY: PG0364 ORIGINAL EFFECTIVE: 04/22/16 LAST REVIEW: 07/26/18 MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site GUIDELINES This policy does not certify benefits or authorization
More informationWendy L Frankel. Chair and Distinguished Professor
1 Wendy L Frankel Chair and Distinguished Professor Case 1 59 y/o woman Abdominal pain No personal or family history of cancer History of colon polyps Colonoscopy Polypoid rectosigmoid mass Biopsy 3 4
More informationNordic Immunohistochemical Quality Control
Nordic Immunohistochemical Quality Control Immunohistochemistry in the classifiation of neoplasias of the alimentary tract & External Quality Assurance of Immunohistochemistry for GI cancer markers Mogens
More informationA 53 year-old woman with a lung mass, right hilar mass and mediastinal adenopathy.
November 2015 Case of the Month A 53 year-old woman with a lung mass, right hilar mass and mediastinal adenopathy. Contributed by: Rasha Salama, M.D., IU Department of Pathology and Laboratory Medicine
More informationThe clinically challenging entity of liver metastasis from tumors of unknown primary
The clinically challenging entity of liver metastasis from tumors of unknown primary Xuchen Zhang, MD, PhD Associate Professor of Pathology Department of Pathology Yale University School of Medicine Liver
More informationperformed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
More informationCODING TUMOUR MORPHOLOGY. Otto Visser
CODING TUMOUR MORPHOLOGY Otto Visser INTRODUCTION The morphology describes the tissue of the tumour closest to normal tissue Well differentiated tumours are closest to normal Undifferentiated tumours show
More informationEARLY ONLINE RELEASE
EARLY ONLINE RELEASE Note: This article was posted on the Archives Web site as an Early Online Release. Early Online Release articles have been peer reviewed, copyedited, and reviewed by the authors. Additional
More informationCase 18. M75. Excision of mass on scalp. Clinically SCC. The best diagnosis is:
Case 18 M75. Excision of mass on scalp. Clinically SCC. The best diagnosis is: A. Pilomatrical carcinoma B. Adnexal carcinoma NOS C. Metastatic squamous cell carcinoma D.Primary squamous cell carcinoma
More informationThe Panel Approach to Diagnostics. Lauren Hopson International Product Specialist Cell Marque Corporation
The Panel Approach to Diagnostics Lauren Hopson International Product Specialist Cell Marque Corporation Cell Marque Rocklin, California About Cell Marque: IVD primary antibody manufacturer Distributors
More informationCutaneous metastases. Thaddeus Mully. University of California, San Francisco Professor, Departments of Pathology and Dermatology
Cutaneous metastases Thaddeus Mully University of California, San Francisco Professor, Departments of Pathology and Dermatology DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Thaddeus Mully Course C005 Essential
More informationCoordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma
Anatomic Pathology / CYTOKERATINS 7 AND 20 IN PROSTATE AND BLADDER CARCINOMAS Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma Nader H. Bassily,
More informationMeasure Description. Denominator Statement
CMS ID/CMS QCDR ID: CAP 18 Title: Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Primary or Metastatic
More informationZyto-Facts Editorial. News for Pathology and Immunohistochemistry. +++ Newsflash +++ Newsflash +++
Zyto-Facts 1-2016 News for Pathology and Immunohistochemistry Editorial The primary site of a tumor is not known in about 3 % to 5 % of all cancer diagnoses. Patients, whose primary site could be identified,
More informationMalignant neoplasms of the gastrointestinal (GI) tract,
Special Section First Chinese American Pathologists Association Diagnostic Pathology Course, Part II Practical Immunohistochemistry in Neoplastic Pathology of the Gastrointestinal Tract, Liver, Biliary
More informationExpression of Cytokeratin 5/6 in Epithelial Neoplasms: An Immunohistochemical Study of 509 Cases
Expression of Cytokeratin 5/6 in Epithelial Neoplasms: An Immunohistochemical Study of 509 Peiguo G. Chu, M.D., Ph.D., Lawrence M. Weiss, M.D. Department of Pathology, City of Hope National Medical Center,
More informationImmunohistochemistry in Bone and Soft Tissue Tumors. Sahar Rassi Zankoul, MD
Immunohistochemistry in Bone and Soft Tissue Tumors Sahar Rassi Zankoul, MD Introduction Bone tumors represent a wide variety of tumors of various origins and malignant potentials. These different tumor
More informationHistological Typing Of Cancer And Precancer Of The Oral Mucosa
Histological Typing Of Cancer And Precancer Of The Oral Mucosa 1 / 7 2 / 7 3 / 7 Histological Typing Of Cancer And Within the last decade, histologic grading has become widely accepted as a powerful indicator
More informationMetastatic cancers can be difficult to diagnose in a. CDH17 Is a More Sensitive Marker for Gastric Adenocarcinoma Than CK20 and CDX2
CDH17 Is a More Sensitive Marker for Gastric Adenocarcinoma Than CK20 and CDX2 David Altree-Tacha, PhD; Jillian Tyrrell, PhD; Thomas Haas, DO Context. CDH17, which is expressed in the intestinal epithelium,
More informationAppendix 4: WHO Classification of Tumours of the pancreas 17
S3.01 The WHO histological tumour type must be recorded. CS3.01a The histological type of the tumour should be recorded based on the current WHO classification 17 (refer to Appendices 4-7). Appendix 4:
More informationInsulinoma-associated protein (INSM1) is a sensitive and specific marker for lung neuroendocrine tumors in cytologic and surgical specimens
Insulinoma-associated protein (INSM1) is a sensitive and specific marker for lung neuroendocrine tumors in cytologic and surgical specimens Kartik Viswanathan, M.D., Ph.D New York Presbyterian - Weill
More informationStudy on the expression of MMP-9 and NF-κB proteins in epithelial ovarian cancer tissue and their clinical value
Study on the expression of MMP-9 and NF-κB proteins in epithelial ovarian cancer tissue and their clinical value Shen Wei 1,a, Chen Juan 2, Li Xiurong 1 and Yin Jie 1 1 Department of Obstetrics and Gynecology,
More informationGastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors
Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors Jaume Capdevila, MD, PhD Vall d'hebron University Hospital Vall d'hebron Institute of Oncology (VHIO)
More informationAmerican Journal of. Medical Case Reports. CAM5.2 Expression in Metastatic Tumours of CNS: A Diagnostic Tool
American Journal of American Journals of Medical Case Reports http://ivyunion.org/index.php/ajmcr/index Medical Case Reports Mathur SK et al. American Journal of Medical Case Reports 2014, 2:1-8 Vol 2,
More informationImmunohistochemistry on Fluid Specimens: Technical Considerations
Immunohistochemistry on Fluid Specimens: Technical Considerations Blake Gilks Dept of Pathology University of British Columbia, Vancouver, BC, Canada Disclosures None Learning Objectives At the end of
More informationDisclosure of Relevant Financial Relationships
Disclosure of Relevant Financial Relationships USCAP requires that all faculty in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS
More informationRadiology Pathology Conference
Radiology Pathology Conference Nadia F. Yusaf, M.D. PGY-3 1/29/2010 Presentation material is for education purposes only. All rights reserved. 2010 URMC Radiology Page 1 of 90 Case 1 60 year- old man presents
More informationFINALIZED SEER SINQ QUESTIONS
0076 Source 1: WHO Class CNS Tumors pgs: 33 MP/H Rules/Histology--Brain and CNS: What is the histology code for a tumor originating in the cerebellum and extending into the fourth ventricle described as
More informationMeasure Specifications Measure Description
CMS ID/CMS QCDR ID: CAP 15 Title: BRAF Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Metastatic Colorectal Adenocarcinoma Specifications Description Denominator
More informationHistopathological diagnosis of CUP
Histopathological diagnosis of CUP Dr Karin Oien karin.oien@glasgow.ac.uk Disclosure slide Dr Karin Oien has no financial interests in any company mentioned in this presentation. Dr Karin Oien is conducting
More informationImmunohistochemical Expression of Cytokeratin 5/6 in Gynaecological Tumors.
ISPUB.COM The Internet Journal of Pathology Volume 13 Number 2 Immunohistochemical Expression of Cytokeratin 5/6 in Gynaecological Tumors. A Baghla, S Choudhry, A Kataria Citation A Baghla, S Choudhry,
More informationCARCINOMA OF UNKNOWN PRIMARY: DIAGNOSTIC APPROACH USING IMMUNOHISTOCHEMISTRY
CARCINOMA OF UNKNOWN PRIMARY: DIAGNOSTIC APPROACH USING IMMUNOHISTOCHEMISTRY Jason L Hornick, MD, PhD Director of Surgical Pathology Director of Immunohistochemistry Brigham and Women s Hospital Associate
More informationThe role of immunohistochemistry in surgical pathology of the uterine corpus and cervix
The role of immunohistochemistry in surgical pathology of the uterine corpus and cervix Prof. Ben Davidson, MD PhD Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
More informationStage 4 gastric adenocarcinoma icd 10
> Stage 4 gastric adenocarcinoma icd 10 stage iii; Carcinoma of colon, stage iv; Colon cancer metastatic to unspecified site; Hereditary nonpolyposis colon cancer; Malignant tumor of colon; Metastasis.
More informationGOBLET CELL CARCINOID. Hanlin L. Wang, MD, PhD University of California Los Angeles
GOBLET CELL CARCINOID Hanlin L. Wang, MD, PhD University of California Los Angeles Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to
More informationGOBLET CELL CARCINOID
GOBLET CELL CARCINOID Hanlin L. Wang, MD, PhD University of California Los Angeles Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to
More informationPancreatic Cytopathology: The Solid Neoplasms
Pancreatic Cytopathology: The Solid Neoplasms Syed Z. Ali, M.D. Professor of Pathology and Radiology Director of Cytopathology The Johns Hopkins Hospital Baltimore, Maryland Pancreatic Cytopathology: Past,
More informationNEW IHC A n t i b o d i e s
NEW IHC Antibodies TABLE OF CONTENTS NEW IHC ANTIBODIES from Cell Marque CITED1 (5H6).... 1 Claudin 7 (5D10F3).... 1 GATA1 (4F5).... 1 Transgelin (2A10C2).... 1 NEW IHC ANTIBODIES using RabMAb Technology
More informationClaudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression
Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Mona A. Abd-Elazeem, Marwa A. Abd- Elazeem Pathology department, Faculty of Medicine, Tanta
More informationRadiology Pathology Conference
Radiology Pathology Conference Sharlin Johnykutty,, MD, Cytopathology Fellow Sara Majewski, MD, Radiology Resident Friday, August 28, 2009 Presentation material is for education purposes only. All rights
More informationDIAGNOSTIC DILEMMA. Case Reports Clinical history. Materials and Methods
DIAGNOSTIC DILEMMA A Metastatic Renal Carcinoid Tumor Presenting as Breast Mass: A Diagnostic Dilemma Farnaz Hasteh, M.D., 1 Robert Pu, M.D., Ph.D., 2 and Claire W. Michael, M.D. 2 * We present clinicopathological
More informationDATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #
DATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #2006-01 CATEGORY: CLARIFICATION SUBJECT: RESCINDMENT - DSQC MEMORANDUM 2002-08 Coding Complex Morphologic Diagnoses (revised 8/02) EFFECTIVE: For Cases
More informationUpdate on 2015 WHO Classification of Lung Adenocarcinoma 1/3/ Mayo Foundation for Medical Education and Research. All rights reserved.
1 Our speaker for this program is Dr. Anja Roden, an associate professor of Laboratory Medicine and Pathology at Mayo Clinic as well as consultant in the Anatomic Pathology Laboratory and co-director of
More informationPapillary Lesions of the Breast A Practical Approach to Diagnosis. (Arch Pathol Lab Med. 2016;140: ; doi: /arpa.
Papillary Lesions of the Breast A Practical Approach to Diagnosis (Arch Pathol Lab Med. 2016;140:1052 1059; doi: 10.5858/arpa.2016-0219-RA) Papillary lesions of the breast Span the spectrum of benign,
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer March 2017 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer January 2015 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationCase: The patient is a 24 year- old female who was found to have multiple mural nodules within the antrum. Solid and cystic components were noted on
Case: The patient is a 24 year- old female who was found to have multiple mural nodules within the antrum. Solid and cystic components were noted on imaging. There is no significant past medical history.
More informationSection 1. Biology of gynaecological cancers: our current understanding
Section 1 Biology of gynaecological cancers: our current understanding Chapter 1 Morphological sub-types of ovarian carcinoma: new developments and pathogenesis W Glenn McCluggage 1 Introduction In most
More informationCASE 4 21/07/2017. Ectopic Prostatic Tissue in Cervix. Female 31. LLETZ for borderline nuclear abnormalities
Female 31 CASE 4 LLETZ for borderline nuclear abnormalities PSA Ectopic Prostatic Tissue in Cervix AJSP 2006;30;209-215 usually incidental microscopic finding usually in ectocervical stroma? developmental
More informationInterventions for non-metastatic squamous cell carcinoma of the skin: a systematic review and pooled analysis of observational studies
Web appendix 2: SEARCH STRATEGIES Interventions for non-metastatic squamous cell carcinoma of the skin: a systematic review and pooled analysis of observational studies MEDLINE 1. exp epidemiologic studies/
More informationWT1, Estrogen Receptor, and Progesterone Receptor as Markers for Breast or Ovarian Primary Sites in Metastatic Adenocarcinoma to Body Fluids
Anatomic Pathology / WT1, ESTROGEN RECEPTOR, AND PROGESTERONE RECEPTOR IN CYTOLOGY OF BODY FLUIDS WT1, Estrogen Receptor, and Progesterone Receptor as Markers for Breast or Ovarian Primary Sites in Metastatic
More informationACCME/Disclosures. Diagnosing Mesothelioma in Limited Tissue Samples. Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016
Diagnosing Mesothelioma in Limited Tissue Samples Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016 Sanja Dacic, MD, PhD University of Pittsburgh ACCME/Disclosures GENERAL RULES
More informationPitfalls in thyroid tumor pathology. Prof.Valdi Pešutić-Pisac MD, PhD
Pitfalls in thyroid tumor pathology Prof.Valdi Pešutić-Pisac MD, PhD Too many or... Tumour herniation through a torn capsule simulating capsular invasion fibrous capsule with a sharp discontinuity, suggestive
More informationDifferential diagnosis of HCC
Hepatocellular Carcinoma Quest for an Ideal Immunohistochemical Panel Sanjay Kakar, MD UCSF Differential diagnosis of HCC Hepatocellular lesions Adenoma, FNH, HG dysplasia Adenocarcinoma CholangioCA, metastasis
More information2018 Surgical Pathology Update: Diagnostic Pearls for the Practicing Pathologist - Volume II
Release Date: January 1, 15.25 AMA PRA Category 1 Credit(s) TM About This CME Teaching Activity This CME Activity is designed to provide a comprehensive review of soft tissue, gastrointestinal, genitourinary,
More informationValue of antimesothelioma HBME 1 in the diagnosis of inflammatory and malignant pleural effusions
Romanian Journal of Morphology and Embryology 2006, 47(4):351 355 ORIGINAL PAPER Value of antimesothelioma HBME 1 in the diagnosis of inflammatory and malignant pleural effusions LILIANA MOCANU 1), ANCA
More informationMucin-producing urothelial-type adenocarcinoma of prostate: report of two cases of a rare and diagnostically challenging entity
& 2005 USCAP, Inc All rights reserved 0893-3952/05 $30.00 www.modernpathology.org Mucin-producing urothelial-type adenocarcinoma of prostate: report of two cases of a rare and diagnostically challenging
More informationThe Incidence and Significance of Villous Change in Adenomatous Polyps
The Incidence and Significance Villous Change in Adenomatous Polyps CHRISTOPHER H. K. FUNC, M.D., AND HARVEY GOLDMAN, M.D. Department Pathology, Harvard Medical School and Beth Israel Hospital, Boston,
More informationDifferentiation of Tumors with Specific Red Cell Adherence (SRCA) test
753 Differentiation of Tumors with Specific Red Cell Adherence (SRCA) test Dr. Abhishek A Mangaonkar *, Dr. A G Valand 1 Intern, Grant Medical College and Sir J.J. Group of Hospitals, Mumbai, India 2 Professor,
More information3/27/2017. Pulmonary Pathology Specialty Conference. Disclosure of Relevant Financial Relationships. Clinical History:
Pulmonary Pathology Specialty Conference Saul Suster, M.D. Medical College of Wisconsin Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position
More informationImmunohistochemical Evaluation of Necrotic Malignant Melanomas
Anatomic Pathology / EVALUATION OF NECROTIC MALIGNANT MELANOMAS Immunohistochemical Evaluation of Necrotic Malignant Melanomas Daisuke Nonaka, MD, Jordan Laser, MD, Rachel Tucker, HTL(ASCP), and Jonathan
More informationROLE OF TTF-1, CK20, AND CK7 IMMUNOHISTOCHEMISTRY FOR DIAGNOSIS OF PRIMARY
Y.C. Su, Y.C. Hsu, and C.Y. Chai ROLE OF TTF-1, CK20, AND CK7 IMMUNOHISTOCHEMISTRY FOR DIAGNOSIS OF PRIMARY AND SECONDARY LUNG ADENOCARCINOMA Yue-Chiu Su 1, Yu-Chang Hsu 2, and Chee-Yin Chai 1,3 Departments
More informationXXV Congreso de la Sociedad Española de Anatomía Patológica y División Española de la International Academy of Pathology
XXV Congreso de la Sociedad Española de Anatomía Patológica y División Española de la International Academy of Pathology NUEVOS FENOTIPOS DEL CÁNCER DE MAMA: NUEVOS PROBLEMAS PARA EL PATÓLOGO? Tienen actualmente
More informationInternational Society of Gynecological Pathologists Symposium 2007
International Society of Gynecological Pathologists Symposium 2007 Anais Malpica, M.D. Department of Pathology The University of Texas M.D. Anderson Cancer Center Grading of Ovarian Cancer Histologic grade
More information57th Annual HSCP Spring Symposium 4/16/2016
An Unusual Malignant Spindle Cell Lesion to Involve the Breast Erinn Downs-Kelly, D.O. Associate Professor of Pathology University of Utah & ARUP Laboratories No disclosures Case 39 y/o female with no
More informationThe PAX8 gene is a member of the paired-box family of
Assessment of the Utility of PAX8 Immunohistochemical Stain in Diagnosing Endocervical Glandular Lesions Li Liang, MD, PhD; Wenxin Zheng, MD; Jinsong Liu, MD, PhD; Sharon X. Liang, MD, PhD Context. PAX8,
More information3/24/2017. Disclosure of Relevant Financial Relationships. Mixed Epithelial Endometrial Carcinoma. ISGyP Endometrial Cancer Project
Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content of CME disclose any relevant financial relationship
More informationSelect problems in cystic pancreatic lesions
Disclosure Select problems in cystic pancreatic lesions Five Prime Therapeutics shareholder Adicet Bio shareholder Bristol-Meyer Squibb advisory board grace.kim@ucsf.edu Pancreatic cystic lesions Intraductal
More informationCerebral Parenchymal Lesions: I. Metastatic Neoplasms
Chapter 4 Cerebral Parenchymal Lesions: I. Metastatic Neoplasms After one has reasonably ruled out the possibility of a nonneoplastic diagnosis (see Chap. 3), one is left with considering a diagnosis of
More informationPSA. HMCK, p63, Racemase. HMCK, p63, Racemase
Case 1 67 year old male presented with gross hematuria H/o acute prostatitis & BPH Urethroscopy: small, polypoid growth with a broad base emanating from the left side of the verumontanum Serum PSA :7 ng/ml
More informationProstate Immunohistochemistry. Literature Interpretation: Caveats. Must be aware of staining pattern of antibody in the relevant tissue
IHC Interpretation: General Principles (1) Prostate Immunohistochemistry Murali Varma Cardiff, UK wptmv@cf.ac.uk Sarajevo Nov 2013 Must be aware of staining pattern of antibody in the relevant tissue Nuclear/cytoplasmic/membranous
More informationMolecular Subtyping of Endometrial Cancer: A ProMisE ing Change
Molecular Subtyping of Endometrial Cancer: A ProMisE ing Change Charles Matthew Quick, M.D. Associate Professor of Pathology Director of Gynecologic Pathology University of Arkansas for Medical Sciences
More informationBreast cancer: IHC classification. Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark
Breast cancer: IHC classification Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark http://upload.wikimedia.org/wikipedia/commons/1/1a/breast.svg
More informationUsefulness of GATA3 and p40 Immunostains in the Diagnosis of Metastatic Urothelial Carcinoma in Cytology Specimens
Original Article Usefulness of GATA3 and p40 Immunostains in the Diagnosis of Metastatic Urothelial Carcinoma in Cytology Specimens Tamar C. Brandler, MD, MS 1 ; Mohamed S. Aziz, MD 1 ; Lisa M. Rosen,
More informationMicroRNA expression profiling and functional analysis in prostate cancer. Marco Folini s.c. Ricerca Traslazionale DOSL
MicroRNA expression profiling and functional analysis in prostate cancer Marco Folini s.c. Ricerca Traslazionale DOSL What are micrornas? For almost three decades, the alteration of protein-coding genes
More informationAccuracy of cell typing in nonsmall cell lung cancer by EBUS/EUS FNA cytological samples
Eur Respir J 2011; 38: 911 917 DOI: 10.1183/09031936.00176410 CopyrightßERS 2011 Accuracy of cell typing in nonsmall cell lung cancer by EBUS/EUS FNA cytological samples W.A.H. Wallace* and D.M. Rassl
More informationROLE OF PROSTATIC BASAL CELL MARKER IN DIAGNOSIS OF PROSTATIC LESIONS
Original Research Article Pathology International Journal of Pharma and Bio Sciences ISSN 0975-6299 ROLE OF PROSTATIC BASAL CELL MARKER IN DIAGNOSIS OF PROSTATIC LESIONS SUBATHRA K* Department of pathology,
More informationTriple Negative Breast Cancer
Triple Negative Breast Cancer Prof. Dr. Pornchai O-charoenrat Division of Head-Neck & Breast Surgery Department of Surgery Faculty of Medicine Siriraj Hospital Breast Cancer Classification Traditional
More informationNPQR Quality Payment Program (QPP) Measures 21_18247_LS.
NPQR Quality Payment Program (QPP) Measures 21_18247_LS MEASURE ID: QPP 99 MEASURE TITLE: Breast Cancer Resection Pathology Reporting pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes)
More informationFellowship in Cytopathology Department of Pathology. All India Institute of Medical Sciences (AIIMS) Jodhpur, Rajasthan, India
Fellowship in Cytopathology Department of Pathology All India Institute of Medical Sciences (AIIMS) Jodhpur, Rajasthan, India Syllabus for Fellowship in Cytopathology: FNAC Direct, Guided, EUS Exfoliative
More information4/12/2018. MUSC Pathology Symposium Kiawah Island April 18, Jesse K. McKenney, MD
MUSC Pathology Symposium Kiawah Island April 18, 2018 Jesse K. McKenney, MD 1 Urothelial Carcinoma with Alternative Differentiation 2 Urothelial Carcinoma with Alternative Differentiation Recognition as
More informationFormat Of ICD-O Terms In Numerical List Each topographic and morphologic term appears only once The first listed term in Bold Type is the Preferred Te
Florida Cancer Data System International Classification of Diseases for Oncology ICD-O-3 1 Basic Concepts Primary Site/Topography Histology/Morphology Behavior Grade/Immunophenotype 2 ICD-O 3 Structure/Format
More informationTHYROID TUMOR DIAGNOSIS: MARKER OF THE MONTH CLUB
THYROID TUMOR DIAGNOSIS: MARKER OF THE MONTH CLUB CHARACTERISTIC OF THE IDEAL TUMOR MARKER Specific Sensitive Easy to perform Easy to interpret Adaptable to FNA Reasonable cost (CHEAP) THYROID TUMOR MARKERS
More informationDiagnostic accuracy of percutaneous renal tumor biopsy May 10 th 2018
Diagnostic accuracy of percutaneous renal tumor biopsy May 10 th 2018 Dr. Tzahi Neuman Dep.Of Pathology Hadassah Medical Center Jerusalem, Israel, (tneuman@hadassah.org.il) Disclosure: 1 no conflicts of
More informationISSN X (Print) Original Research Article. DOI: /sjams
DOI: 10.21276/sjams.2016.4.7.33 Scholars Journal of Applied Medical Sciences (SJAMS) Sch. J. App. Med. Sci., 2016; 4(7C):2468-2473 Scholars Academic and Scientific Publisher (An International Publisher
More informationInstructions for Coding Grade for 2014+
Instructions for Coding for 2014+ GRADE, DIFFERENTIATION OR CELL INDICATOR Item Length: 1 NAACCR Item #: 440 NAACCR Name:, Differentiation for solid tumors (Codes 1, 2, 3, 4, 9) and Cell Indicator for
More informationCANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I
CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I Changes and Clarifications 16 th Edition April 15, 2016 Quick Look- Updates to Volume
More informationSATB1 and 2 in colorectal cancer
Carcinogenesis, 2015, Vol. 36, No. 2, 186 191 doi:10.1093/carcin/bgu322 Advance Access publication December 27, 2014 Review review SATB1 and 2 in colorectal cancer Jason Brocato and Max Costa* Department
More informationMesothelioma: diagnostic challenges from a pathological perspective. Naseema Vorajee August 2016
Mesothelioma: diagnostic challenges from a pathological perspective Naseema Vorajee August 2016 Naseema.vorajee@nhls.ac.za Pleural diseases (whether neoplastic, reactive or infective) may have similar
More informationSupplementary Information
Supplementary Information Supplementary Figure 1. Western blotting with ERβ antibodies Full blots corresponding to Fig. 2, along with replicated experiments at different time points, different batches,
More informationWhat I Learned from 3 Cases and 3 Antibodies
What I Learned from 3 Cases and 3 Antibodies Melinda Sanders, M.D Vanderbilt University Medical Center Professor of Pathology Consultant in Breast Pathology Disclosure of Relevant Financial Relationships
More information